{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:04:00Z","timestamp":1782975840286,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Eli Lilly and Company"],"award-info":[{"award-number":["Eli Lilly and Company"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL): measures of Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) Symptoms, Mantle Cell Lymphoma (MCL) Symptoms, and an Expanded Fatigue measure. The objective of this study was to assess psychometric properties of the measures and provide guidance for interpretation by identifying thresholds for determining meaningful within-patient change (MWPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Psychometric properties of the CLL\/SLL-related Symptoms, MCL-related Symptoms, and Expanded Fatigue measures were assessed using classical test theory (CTT) and Rasch measurement theory (RMT) using blinded data collected from two phase 3 trials in participants with CLL\/SLL (BRUIN-CLL-321,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009211) and MCL (BRUIN-MCL-321,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009523). CTT analyses assessed reliability, construct validity and ability to detect change, while RMT analyses explored adequacy of summing items to generate summary scores. MWPC for each score was estimated using anchor-based and distribution-based methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The three measures demonstrated adequate internal consistency and test-retest reliability, and strong evidence of construct validity. Each showed a good ability to detect worsening and, to a lesser degree, improvement. RMT analyses confirmed adequacy of the response scales but suggested suboptimal targeting for participants with the lowest symptoms severity. For the two symptoms-related measures, items related to fatigue were over-discriminating, suggesting that they are driving the measures. Analyses of MWPC resulted in the following estimates: for the CLL\/SLL-related Symptoms score, an improvement of -15.38 points (worsening unable to be estimated); for the MCL-related Symptoms score, an improvement of -10.25 points and a worsening of 5.12 points; and for the Expanded Fatigue score, an improvement\u2009-16.66 points in both CLL\/SLL and MCL populations and a worsening of 11.11 points in participants with MCL (unable to be estimated in CLL\/SLL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CLL\/SLL-related Symptoms, MCL-related Symptoms, and Expanded Fatigue measures showed strong psychometric properties in both CTT and RMT frameworks. Combined with previously published qualitative data, this research showed that the measures are appropriate for use in clinical trials of participants with CLL\/SLL and MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registrations<\/jats:title>\n                    <jats:p>\n                      BRUIN-CLL-321, NCT04666038. Registered 07 December 2020,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04666038\" ext-link-type=\"uri\">https:\/\/www.clinicaltrials.gov\/study\/NCT04666038<\/jats:ext-link>\n                      ; BRUIN-MCL-321, NCT04662255, Registered 04 December 2020,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04662255\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT04662255<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01126-w","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:56:30Z","timestamp":1782129390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library"],"prefix":"10.1186","volume":"10","author":[{"given":"Ang\u00e9ly","family":"Loubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Creel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naleen Raj","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Abada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalin","family":"Payakachat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1126_CR1","unstructured":"FDA (2024) Core patient-reported outcomes in cancer clinical trials: guidance for industry"},{"issue":"12","key":"1126_CR2","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1007\/s11136-015-1039-y","volume":"24","author":"KM Holtzer-Goor","year":"2015","unstructured":"Holtzer-Goor KM et al (2015) Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Qual Life Res 24(12):2895\u20132906","journal-title":"Qual Life Res"},{"issue":"11","key":"1126_CR3","first-page":"1862","volume":"31","author":"SA Rosenberg","year":"1971","unstructured":"Rosenberg SA et al (1971) Report of the committee on Hodgkin\u2019s disease staging procedures. Cancer Res 31(11):1862\u20131863","journal-title":"Cancer Res"},{"issue":"1","key":"1126_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41687-024-00683-2","volume":"8","author":"JT Markowitz","year":"2024","unstructured":"Markowitz JT et al (2024) Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. J Patient Rep Outcomes 8(1):8","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"1126_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1179\/1024533215Z.000000000351","volume":"20","author":"J Okikiolu","year":"2015","unstructured":"Okikiolu J, McNamara C (2015) Lymphoid neoplasms. Hematology 20(3):182\u2013183","journal-title":"Hematology"},{"issue":"16","key":"1126_CR6","first-page":"2497","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC et al (2015) Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood J Am Soc Hematol 125(16):2497\u20132506","journal-title":"Blood J Am Soc Hematol"},{"key":"1126_CR7","doi-asserted-by":"crossref","unstructured":"St-Pierre F, Ma S (2022) Use of BTK inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a practical guidance. Blood lymphatic cancer: target ther 81\u201398","DOI":"10.2147\/BLCTT.S326627"},{"issue":"11","key":"1126_CR8","first-page":"1256","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML (2016) Mantle Cell Lymphoma J Clin Oncol 34(11):1256\u20131269","journal-title":"Mantle Cell Lymphoma J Clin Oncol"},{"issue":"6","key":"1126_CR9","first-page":"1561","volume":"4","author":"SE Kalloger","year":"2024","unstructured":"Kalloger SE et al (2024) Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition\u2019s 2022 Global Patient Survey. Cancer Res Commun 4(6):1561\u20131565","journal-title":"Cancer Res Commun"},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40164-019-0126-0","volume":"8","author":"A Ladha","year":"2019","unstructured":"Ladha A et al (2019) Mantle cell lymphoma and its management: where are we now? Exp Hematol Oncol 8:2","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"1126_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjh.18072","volume":"197","author":"S Oerlemans","year":"2022","unstructured":"Oerlemans S et al (2022) International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health\u2010related quality of life for patients with chronic lymphocytic leukaemia. Br J Haematol 197(4):431\u2013441","journal-title":"Br J Haematol"},{"issue":"2","key":"1126_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11136-017-1718-y","volume":"27","author":"L van de Poll-Franse","year":"2018","unstructured":"van de Poll-Franse L et al (2018) International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high-and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Qual Life Res 27(2):333\u2013345","journal-title":"Qual Life Res"},{"issue":"Supplement 1","key":"1126_CR13","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood-2024-198147","volume":"144","author":"JP Sharman","year":"2024","unstructured":"Sharman JP et al (2024) BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Blood 144(Supplement 1):886\u2013886","journal-title":"Blood"},{"issue":"36","key":"1126_CR14","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.2217\/fon-2022-0976","volume":"18","author":"TA Eyre","year":"2022","unstructured":"Eyre TA et al (2022) BRUIN MCL-321: Phase III Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in BTK Inhibitor Naive Mantle Cell Lymphoma. Future Oncol 18(36):3961\u20133969","journal-title":"Future Oncol"},{"issue":"5","key":"1126_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"1126_CR16","unstructured":"Fayers PM et al (1999) EORTC QLQ-C30 scoring manual. Eortc"},{"key":"1126_CR17","volume-title":"Psychometric Theory","author":"JC Nunally","year":"1994","unstructured":"Nunally JC, Bernstein IH (1994) Psychometric Theory, 3rd edn. McGraw-Hill Inc, New York","edition":"3"},{"issue":"3","key":"1126_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","volume":"18","author":"H Akoglu","year":"2018","unstructured":"Akoglu H (2018) User\u2019s guide to correlation coefficients. Turk J Emerg Med 18(3):91\u201393","journal-title":"Turk J Emerg Med"},{"key":"1126_CR19","unstructured":"Dancey CP, Reidy J (2020) Statistics without maths for psychology. 8th edition. Harlow, England; New York: Pearson. volumes cm"},{"key":"1126_CR20","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates. xxi, 567 p"},{"key":"1126_CR21","unstructured":"Rasch G (1960) Copenhagen: Danish institute for education research (expanded edition (1980) with foreword and afterword by B.D. Wright, Chicago: The University of Chicago Press, 1980. Reprinted Chicago: MESA Press, 1993"},{"key":"1126_CR22","unstructured":"Andrich D (1988) Rasch Models for Measurement. Sage University Paper series on Quantitative Applications in the Social Sciences, Vol. 07-068. Beverly Hills: Sage Publications"},{"issue":"12","key":"1126_CR23","first-page":"1","volume":"13","author":"J Hobart","year":"2009","unstructured":"Hobart J, Cano S (2009) Improving the evaluation of therapeutic intervention in MS: the role of new psychometric methods. Monogr UK Health Technol Assess Programme 13(12):1\u2013200","journal-title":"Monogr UK Health Technol Assess Programme"},{"issue":"1","key":"1126_CR24","first-page":"905","volume":"17","author":"B Wright","year":"2003","unstructured":"Wright B (2003) Rack and stack: time 1 vs. time 2. Rasch Meas Trans 17(1):905\u2013906","journal-title":"Rasch Meas Trans"},{"key":"1126_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0191-8869(03)00164-8","volume":"36","author":"C Hagquist","year":"2004","unstructured":"Hagquist C, Andrich D (2004) Is the Sense of Coherence instrument applicable on adolescents? A latent trait analysis using Rasch modelling. Pers Indiv Differ 36:955\u2013968","journal-title":"Pers Indiv Differ"},{"issue":"Pt 1","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/brain\/awh675","volume":"129","author":"JC Hobart","year":"2006","unstructured":"Hobart JC et al (2006) Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129(Pt 1):224\u2013234","journal-title":"Brain"},{"key":"1126_CR27","volume-title":"Rating scale analysis: Rasch measurement","author":"BD Wright","year":"1982","unstructured":"Wright BD, Masters G (1982) Rating scale analysis: Rasch measurement. MESA, Chicago, IL"},{"issue":"1","key":"1126_CR28","first-page":"95","volume":"9","author":"D Andrich","year":"1982","unstructured":"Andrich D (1982) An index of person separation in latent trait theory, the traditional KR20 index, and the Guttman scale response pattern. Educational Psychol Res 9(1):95\u2013104","journal-title":"Educational Psychol Res"},{"key":"1126_CR29","unstructured":"Modus Outcomes, BRUIN 18001 Patient-Reported Outcome (PRO) Psychometrics Report, v2"},{"key":"1126_CR30","doi-asserted-by":"crossref","unstructured":"Loubert A et al (2023) Psychometric evaluation of customized lymphoma-specific symptom measures using the EORTC QLQ-C30 and Item Library: Data from a phase 1\/2 clinical trial of pirtobrutinib. ISPOR 2023. Boston","DOI":"10.1016\/j.jval.2023.03.188"},{"issue":"2","key":"1126_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D et al (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102\u2013109","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1126_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1477-7525-4-65","volume":"4","author":"MJ Atkinson","year":"2006","unstructured":"Atkinson MJ, Lennox RD (2006) Extending basic principles of measurement models to the design and validation of patient reported outcomes. Health Qual Life Outcomes 4(1):65","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1126_CR33","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11136-022-03181-4","volume":"32","author":"K Cocks","year":"2023","unstructured":"Cocks K, Buchanan J (2023) How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales. Qual Life Res 32(5):1247\u20131253","journal-title":"Qual Life Res"},{"issue":"1","key":"1126_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144","journal-title":"J Clin Oncol"},{"key":"1126_CR35","doi-asserted-by":"crossref","unstructured":"Embretson SE, Reise SP (2000) Item response theory for psychologists. Psychology Press","DOI":"10.1037\/10519-153"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01126-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:54:06Z","timestamp":1782971646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01126-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01126-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols were approved by the institutional review boards or independent ethics committees overseeing each site. The studies were done in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws. All patients provided written informed consent. The studies were registered on\n                      \n                      (BRUIN-CLL-321 identifier; NCT04666038, BRUIN-MCL-321 identifier; NCT04662255).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.C., A.R, and A.L., declares employment with Modus Outcomes, and a service contract with Eli Lilly. N.R.B., A.S.R., L.M.H., P.A., and N.P. declares employment with Eli Lilly and Company with minor stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}